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effect of treatment characteristics of upper extremity interven-
tions on the decision of tetraplegic subjects to accept treatment.
METHOD: A discrete choice experiment (DCE) was performed,
where treatment characteristics were obtained to establish dif-
ferent treatment scenarios. Seven different treatment character-
istics were obtained from a panel of international experts.
Tetraplegics were offered 20 sets of two different treatment 
scenarios and asked to select the best scenario. RESULTS: A 
total of 47 tetraplegic subjects with C5–6 lesions, motor group
M1–4 were selected. Relative importance of treatment charac-
teristics were: intervention type (surgery or surgery with FES
implant) 13%, number of operations 15%, in patient rehabili-
tation period 22%, ambulant rehabilitation period 9%, compli-
cation rate 15%, improvement of elbow function 10%,
improvement of hand function 15%. Effects of various changes
of treatment protocols were determined. An inpatient rehabili-
tation period of maximum 4 weeks increases preference for
treatment with 32%. One instead of two operative procedures
increases the preference with 25%. CONCLUSION: In-patient
rehabilitation period appears to have the greatest impact on the
decision by patients to have surgery or not. Implantation of a
neural implant is not the main reason for not accepting this type
of treatment.
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OBJECTIVES: The primary objective is to evaluate health, non-
health cost and utilities differences between Parkinson patients
with diagnosis performed through SPECT (Single Proton Emis-
sion Computerized Tomography) and patients diagnosed tradi-
tionally. METHODS: This economic analysis is part of the
prospective, multicentre, observational study DIAPASON (Diag-
nosis of Parkinson’s Disease: Economics and Outcomes Impact),
which involved 17 neurology centers. The present poster presents
the preliminary economic results. Inclusion criteria: all subjects
with suspect parkinsonism, “de novo” patients or in dopamin-
ergic therapy for 3 months at the most. Exclusion criteria: subject
with dementia senile, subjects treated with antidopaminergic
drugs, subjects with iatrogenic forms of disease already known
or clear vascular lesions of substantia nigra or caudato or
putamen. The prospectives used in the study were: national
health system (NHS) and society. Data were collected using an
electronic case report form. Utilities were calculated using the
EuroQol (EQ-5D) questionnaire. RESULTS: In November 2004,
147 patients (50 NO SPECT, 97 SPECT) had already performed
the second visit. For both ﬁrst and second visit the total cost for
patients with diagnosis performed through SPECT was higher
than that obtained for patients diagnosed traditionally: the mean
health cost supported by NHS per patient was €2,577.79
(€1,562.63 for NO SPECT patients and €3,024.00 for SPECT
ones), and mean non health cost obtained per patient was
€3,553.56 (€3923.44 for SPECT patients, €2712.08 for NO
SPECT patients). For subjects diagnosed traditionally the cost
per QALYs gained was €36,225.2 compared to €15,291.6 for
SPECT patients group. CONCLUSION: The introduction of
new technologies, as SPECT, and the use of new radiolabelled
drugs concur to improve early diagnosis of Parkinson’s disease
and related diseases. Diagnosis using SPECT has health and non
health cost higher than traditional diagnosis, but a cost-utility
analysis demonstrate its cost saving role in comparison with tra-
ditional diagnosis.
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OBJECTIVE: Assess the cost-utility of rasagiline, entacapone
and standard care (levodopa) in Parkinson’s disease (PD) patients
with motor ﬂuctuations in Finland. METHODS: A 2-year prob-
abilistic Markov model with 3 health states: £25% off-time/day’,
‘>25% off-time/day’ and ‘dead’ was used. Model inputs included
transition probabilities from randomised clinical trials, utilities
from a preference measurement study and costs and resources
from a Finnish cost-of-illness study. Effectiveness measures were
Quality Adjusted Life Years (QALYs) and number of months
spent with £25% off-time/day. The primary analysis was per-
formed from the societal perspective. Extensive sensitivity and
subgroup analyses on severe patients were performed. A parity
price was assumed for rasagiline and entacapone based on
WHO-DDD. RESULTS: Over 2 years, rasagiline appeared to
show both greater effectiveness and cost reductions compared
with standard care (0.38 additional QALYs, over 55% addi-
tional time spent with £25% off-time/day and €900 savings
(95% CI: [-€3400; €1090]) per treated patient. Rasagiline and
entacapone yielded similar effectiveness and costs. A trend in
favour of rasagiline was observed in the severe patient subgroup
(approximately €660 total cost savings/patient). Sensitivity
analyses conﬁrmed robustness of the results vs. standard care.
Results vs. entacapone were sensitive to changes in transition
probabilities and drug prices. CONCLUSION: This economic
model supports the use of rasagiline as a cost-effective treatment
compared with levodopa alone and combined with entacapone
in PD patients with motor ﬂuctuations in Finland. Further
improvements of the model should be applied to different set-
tings to conﬁrm these results.
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OBJECTIVE: To explore costs and health beneﬁts of replacing
conventional oral therapy with intraduodenal infusion of car-
bidopa/levodopa (Duodopa®) for severe Parkinson’s disease
(PD). METHODS: In the DIREQT trial 24 patients aged 50–79
years with Hoehn & Yahr stage 2.5–4.0 (at best) were ran-
domised to receive either three weeks of conventional oral
therapy followed by three weeks of Duodopa, or vice versa.
Later, patients could choose to switch permanently to Duodopa.
Health Related Quality of Life (HRQOL) was recorded with the
15D instrument at entry into the trial, during the trial, and then
at 8 follow-ups during the subsequent 6 months. Use of health
care was registered before, during and after the trial. Two-year
costs and health consequences of Duodopa and conventional
therapy were estimated in a decision analytic model. Costs were
based on market prices and customary charges in Sweden.
RESULTS: The mean quality-of-life scores were 0.77 for
Duodopa and 0.72 for conventional therapy with considerable
variation in scores for individual patients over time. The
expected two year cost was $93,600 for Duodopa and $28,700
for conventional oral therapy. The expected number of Quality
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Adjusted Life Years (QALYs) was 1.48 and 1.42 respectively, or
$1.02 mill. per additional QALY (all values discounted at 3%).
This amount would be $199,000 if patients used apomorphine
as conventional therapy, $124.00 if EQ-5D were used to measure
HRQOL, $99,000 if indirect costs were included. If Duodopa
improves disease severity by one H&Y stage, the therapy will 
be cost-saving. CONCLUSIONS: The cost-effectiveness of
Duodopa depends in particular on the cost of alternative thera-
pies (i.e. apomorphine and oral drugs) and the extent to which
Duodopa postpones PD progression. Also, the method for cap-
turing quality-of-life has a considerable impact on the cost-effec-
tiveness ratio. The study indicates that variability in utility scores
may be much greater than previously anticipated.
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OBJECTIVE: To estimate for use in economic modeling, the
time-dependent effects of deep brain stimulation (DBS) in
patients with Parkinson’s Disease (PD) using meta-analysis of
case series. METHODS: A discrete event simulation of the
course of advanced PD was created. It requires time-dependent
functions of the effects of DBS. To obtain these, we searched the
PUBMED, OVID and the Science Citation Index databases
between 1980 and 2004 for papers reporting longitudinal expe-
rience with DBS. Data were extracted by three expert reviewers.
The effect of DBS was measured at various time-points relative
to baseline, while on and off medication. Time-dependent
growth curves were developed by ﬁtting the estimates as func-
tions of time under ﬁxed and random-effects models. RESULTS:
Comparisons to baseline in the 85 studies retained showed that
while off medication, activating the stimulator improved ADL
rapidly (by 50.0% at 3 months) but then improvement declined
slowly following a quadratic polynomial. The effect was much
weaker and decline linearly while on medication but levodopa
dose declined steadily, from a reduction of 590.52 (439.9–741.2)
mg at 3 months to 633.8 (497.4–770.2) mg after 1 year. Motor
skills improved by 47.2% and then more slowly following a frac-
tional polynomial curve. CONCLUSION: These growth curves
will be used to estimate the course of individual patients in sim-
ulation providing much more accurate reﬂection of the actual
effects than traditional point estimates or transition probabili-
ties. Given that studies can be either too small or too limited in
scope to provide sound estimates of the effect of treatment, the
results of meta-analytic curve ﬁtting can be used as precise inputs
to build an economic model.
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OBJECTIVES: To measure the average health care cost per
patient with relapsing remitting multiple sclerosis (RRMS) by
level of severity in Portugal. Additionally, and in contrast to pre-
vious studies, the health care cost of a relapse by severity level
is also calculated. METHODS: The study adopts the perspective
of the National Health Service (NHS) and carries out a cost of
treatment analysis. Information on treatment proﬁles and
resource use was gathered through a modiﬁed Delphi Panel
involving eight specialist physicians from different hospitals
throughout the country. Each completed a questionnaire based
on four clinical cases representing categories of the Expanded
Disability Severity Scale (EDSS). Information was collected on
the use of inpatient care, pharmaceuticals, ambulatory visits, and
various other resources. These were valued using national infor-
mation on unit costs from a variety of sources. RESULTS: Total
health care costs per patient, in 2003, were estimated to range
from €11,515 (EDSS £ 3) to €22,876 (EDSS ≥ 6.5). At each level
of severity the cost of treatment rises with the most signiﬁcant
increase occurring between EDSS £ 3 and 3.5 £ EDSS ≥ 4.5. The
highest expenditures are associated with the use of interferons
(between 44% and 82% of the total costs). When patients have
a relapse, health care costs vary between €3412 (EDSS £ 3) and
€6718 (EDSS ≥ 6.5). At intermediate EDSS levels the costs of a
relapse are €4422 for 3.5 £ EDSS ≥ 4.5 and €6495 for 5 £ EDSS
≥ 6. The most signiﬁcant cost component for relapses is that
related to inpatient stays. CONCLUSIONS: Though the number
of persons with MS in Portugal is small (estimates suggest
around 5000 patients), the costs to the health system are very
large. Therapeutic strategies that reduce the impact of the disease
(e.g. relapse avoidance) can bring about signiﬁcant cost-savings.
The results may be used as input to cost-effectiveness analyses
and more widely in health care planning and policy.
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OBJECTIVES: During the last decade, the introduction of new
disease-modifying drugs (DMDs) for MS gave rise to a number
of studies on the economic burden of the disease and the cost-
effectiveness of different treatment options. Since these surveys
were conducted before DMDs were established as part of stan-
dard treatment regimens, there is a need for up-to-date cost-of-
illness studies that can be used for the economic evaluation of
new treatments. Therefore, European Health Economics has
conducted a European-wide, cross-sectional bottom-up survey
on the costs of MS, involving at least nine countries.
METHODS: The study used a standardised mailed questionnaire
providing data on demographics, direct medical and non-medical
costs, informal care needs, productivity losses, relapses, utility
and fatigue. RESULTS: The results were analysed by country,
both for the whole sample and by level of disease severity mea-
sured with the Expanded Disability Status Scale (EDSS). Patients
were recruited by MS clinics and MS societies, and the response
rate ranged between 35% and 72%. Overall, the study includes
over 10,000 patients. The samples per country are thus sufﬁ-
ciently large to analyse the change in costs and utility for all
levels of disease severity. For example, in Sweden, the total
annual cost per MS patient was estimated at €53,580, with costs
increasing sevenfold for patients with severe disease compared
to patients with no or very mild disability, from €16,338 to
€116,502. DMDs were used by 43% of patients and accounted
for 11% of total costs. In addition, analysis of variations across
countries illustrates the impact of different health care and eco-
nomic systems on patient management, total costs and distribu-
tion of resources. For example, services represented 29% of total
costs in Sweden, due to a unique extensive home service avail-
able to severe patients. CONCLUSIONS: This alternative to
institutionalisation reduces nursing home costs and informal care
needs.
